Wall Street brokerages expect EXACT Sciences Co. (NASDAQ:EXAS) to post ($0.56) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for EXACT Sciences’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.52). EXACT Sciences posted earnings per share of ($0.30) in the same quarter last year, which would indicate a negative year-over-year growth rate of 86.7%. The company is scheduled to announce its next earnings results after the market closes on Tuesday, July 30th.
On average, analysts expect that EXACT Sciences will report full-year earnings of ($2.18) per share for the current financial year, with EPS estimates ranging from ($2.26) to ($2.06). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.38) to ($0.49). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover EXACT Sciences.
EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.01). EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The firm had revenue of $162.00 million during the quarter, compared to analysts’ expectations of $153.07 million. During the same period in the prior year, the company posted ($0.33) earnings per share. The company’s revenue for the quarter was up 79.4% on a year-over-year basis.
EXAS has been the topic of a number of recent analyst reports. Craig Hallum increased their price objective on shares of 1-800-Flowers.Com from $26.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Jefferies Financial Group increased their price objective on shares of EXACT Sciences from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Canaccord Genuity increased their price objective on shares of TELUS from C$51.00 to C$52.00 in a research report on Wednesday, May 1st. BTIG Research increased their price objective on shares of Apple to $234.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, BidaskClub raised shares of Misonix from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 3rd. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. EXACT Sciences currently has a consensus rating of “Buy” and an average target price of $108.45.
Several institutional investors have recently modified their holdings of the company. IFM Investors Pty Ltd acquired a new position in shares of EXACT Sciences in the 2nd quarter valued at $961,000. Legacy Financial Strategies LLC acquired a new position in shares of EXACT Sciences in the 2nd quarter valued at $215,000. Nisa Investment Advisors LLC boosted its holdings in shares of EXACT Sciences by 779.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 27,250 shares of the medical research company’s stock valued at $3,217,000 after buying an additional 24,150 shares in the last quarter. Orgel Wealth Management LLC acquired a new position in shares of EXACT Sciences in the 2nd quarter valued at $224,000. Finally, Handelsbanken Fonder AB boosted its holdings in shares of EXACT Sciences by 18.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 190,000 shares of the medical research company’s stock valued at $22,428,000 after buying an additional 30,000 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.
Shares of NASDAQ:EXAS traded down $1.24 during trading hours on Thursday, reaching $114.95. The stock had a trading volume of 921,298 shares, compared to its average volume of 1,713,290. EXACT Sciences has a 1 year low of $47.78 and a 1 year high of $121.98. The business’s 50 day moving average is $111.70. The company has a quick ratio of 8.13, a current ratio of 8.39 and a debt-to-equity ratio of 1.02. The stock has a market cap of $14.83 billion, a PE ratio of -84.52 and a beta of 1.65.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Further Reading: How does the Beige Book influence monetary policy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.